This is the authors' abstract. We don't add key points for this paper.
The COVID-19 pandemic posed a significant public health stressor, necessitating a robust understanding of SARS-CoV-2 transmission dynamics and the longitudinal evolution of population immunity. This study evaluates anti-SARS-CoV-2 seroprevalence in Tirana, Albania, from 2020 to 2023, quantifying the relative contributions of natural infection, vaccination, and hybrid immunity. Five cross-sectional serosurveys were conducted (June 2020–April 2023) among adults aged 18–70 years. Participants were randomly selected from five primary urban healthcare centers. Serological status was determined via enzyme-linked immunosorbent assays (ELISA) detecting IgG antibodies against SARS-CoV-2 spike (S1) and nucleoprotein (N) antigens. Anti-S1 IgG seroprevalence escalated from 7.5% in June 2020 to 48.2% by December 2020. Prevalence reached 71.7% in August 2021, and plateaued at 93.1% in August 2022 and 93.9% by April 2023. Notably, hybrid immunity prevalence surged from 19.9% in 2021 to 56.0% in 2022. Mean antibody titers in 2022 were 2.4-fold higher than in 2021, indicating a potent immune response synergized by vaccination and prior infection. By late 2022, the Albanian urban population reached a high immunity threshold, primarily driven by the expansion of hybrid immunity. While these levels suggest a transition toward endemicity, targeted vaccination remains critical for vulnerable cohorts. This study provides a framework for long-term serological surveillance and informs future immunization strategies in similar epidemiological settings.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sulcebe et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: